Sugi Predict

Sugi Predict / Compounds / SCHEMBL6461006

SCHEMBL6461006

SCHEMBL6461006

Fc1n[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.58
▸ GAA P10253 2/20 0.58
▸ PDPK1 O15530 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ IDO1 P14902 3/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ ALPL P05186 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TTK P33981 1/20 0.54
▸ MAPK10 P53779 1/20 0.54
▸ CYP1A2 P05177 1/20 0.48
▸ FADS1 O60427 1/20 0.46
▸ LRRK2 Q5S007 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ YTHDC1 Q96MU7 1/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ FLT1 P17948 1/20 0.43
▸ AURKA O14965 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29879486 1.00 KDM4E (0.58) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL1672674 0.75 IDO1 (0.78) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL9407409 0.73 KDM4E (0.60) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL29481432 0.73 PDPK1 (1.00) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL18878 0.73 PDPK1 (1.00) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL16012918 0.73 ATM (0.57) KDM4EGAAALDH1A1
SCHEMBL14095607 0.73 ITK (0.49) KDM4EGAAPDPK1ALDH1A1FADS1
SCHEMBL5377572 0.73 ALDH1A1 (0.71) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL962678 0.71 KDM4E (0.58) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL130625 0.71 CYP1A2 (0.70) KDM4EGAAPDPK1CYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024193328-A1 INDAZOLE SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 汤亚杰 2024-09-26 — — WO claimed
CN-115669669-A Composition containing indoxacarb and tebuconazole as well as preparation method and application thereof 江苏七洲绿色化工股份有限公司 2023-02-03 — — CN claimed
CN-112118737-B Emulsifiable concentrate formulations of SDHI fungicides FMC公司 2022-10-28 — — CN claimed
CN-112118737-A Emulsifiable concentrate formulations of SDHI fungicides FMC公司 2020-12-22 — — CN claimed
CN-105399697-A Amino sulfonyl compound, preparation method and uses thereof SUZHOU WANGSHAN WANGSHUI BIOMEDICAL CO LTD 2016-03-16 — — CN claimed
EP-4722209-A1 PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Shenogen Pharma Group (CN) 2026-04-08 — — EP disclosed
CN-120247804-A Preparation method of 5-bromo-4-fluoro-1-methylindazole 杭州国瑞生物科技有限公司 2025-07-04 — — CN disclosed
WO-2024245169-A1 PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 北京盛诺基医药科技股份有限公司 2024-12-05 — — WO disclosed
WO-2024193328-A1 INDAZOLE SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 汤亚杰 2024-09-26 — — WO disclosed
WO-2024178219-A1 1-ACYL-3-AMINOINDAZOLES FOR TREATING CYSTIC FIBROSIS SHOICHET BRIAN (US) 2024-08-29 — — WO disclosed
US-20240083913-A1 Small Molecule Inhibitors of KRAS G12C Mutant MERCK SHARP & DOHME LLC 2024-03-14 — — US disclosed
US-20240043448-A1 Small Molecule Inhibitors of KRAS G12C Mutant MERCK SHARP & DOHME LLC 2024-02-08 — — US disclosed
US-20030181463-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-09-25 — — US disclosed
US-6610692-B1 Anticoagulants MERCK & CO., INC. 2003-08-26 — — US disclosed
US-6476034-B2 AIDS THERAPY BRISTOL-MYERS SQUIBB COMPANY 2002-11-05 — — US disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 — — US disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 — — US disclosed
EP-1124822-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2002-04-03 — — EP disclosed
EP-1124822-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2001-08-22 — — EP disclosed
WO-2000026211-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2000-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 KDM4E 462/4885GAA 1346/4885PDPK1 2673/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 KDM4E 462/4885GAA 1346/4885PDPK1 2673/4885
US-20240083913-A1 Small Molecule Inhibitors of KRAS G12C Mutant KRAS, NRAS, HRAS KDM4E 2018/4885GAA 1914/4885PDPK1 1527/4885
US-20240043448-A1 Small Molecule Inhibitors of KRAS G12C Mutant KRAS, NRAS, HRAS KDM4E 2018/4885GAA 1914/4885PDPK1 1527/4885
US-20030181463-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 KDM4E 462/4885GAA 1346/4885PDPK1 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.